Skip to main content

Table 1 Ongoing (recruiting or active) clinical trials for CpG ODNs. Results were generated by searching ClinicalTrials.gov with queries “Cancer” and X, where X was “CpG,” “SD-101,” “IMO-2125,” “MGN1703,” “SMP-001,” “CSI-2,” or “GNKG168.” Trials were filtered for recruiting, active not recruiting, or enrolling by invitation

From: The promise and challenge of cancer microbiome research

NCT number Sponsors Study location Disease CpG ODN Combination therapy Phase
NCT03831295 Ronald Levy
Bristol-Myers Squibb
Stanford Cancer Institute Palo Alto, Palo Alto, CA, USA Malignant solid neoplasm SD-101 BMS 986178 (anti-OX40) 1
NCT03410901 Ronald Levy
National Cancer Institute (NCI)
Stanford University, School of Medicine, CA, USA Lymphoma SD-101 BMS 986178, radiation 1
NCT02927964 Robert Lowsky
Janssen, LP
National Institutes of Health (NIH)
Stanford University, School of Medicine, CA, USA Lymphoma SD-101 Ibrutinib (BTK inhibitor), radiation 1, 2
NCT03007732 Lawrence Fong
Prostate Cancer Foundation
Merck Sharp & Dohme Corp.
Dynavax Technologies Corporation
University of California San Francisco, San Francisco, CA, USA Prostatic neoplasm SD-101 Pembrolizumab, androgen deprivation therapy, radiation 2
NCT04050085 University of California, Davis
National Cancer Institute (NCI)
Bristol-Myers Squibb
Dynavax Technologies Corporation
University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA Metastatic/refractory pancreatic cancer, stage IV pancreatic cancer SD-101 Nivolumab (anti-PD-1), radiation 1
NCT02521870 Dynavax Technologies Corporation
Merck Sharp & Dohme Corp.
45 study locations Metastatic melanoma, head neck cancer SD-101 Pembrolizumab (anti-PD-1) 1, 2
NCT03322384 University of California, Davis University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA Lymphoma, advanced solid tumors SD-101 Epacadostat (IDO1 inhibitor), radiation 1, 2
NCT01042379 QuantumLeap Healthcare Collaborative 26 study locations Breast neoplasms, tumors, cancer, angiosarcoma SD-101 Pembrolizumab (anti-PD-1) 2
NCT03438318 Checkmate Pharmaceuticals
Novella Clinical
5 study locations Non-small cell lung cancer CMP-001 Atezolizumab (anti-PD-L1), radiation 1
NCT03507699 Sheba Medical Center
Checkmate Pharmaceuticals
Bristol-Myers Squibb
Sheba Medical Center, Ramat Gan, Israel Malignant colorectal neoplasms, liver metastases CMP-001 Nivolumab, ipilimumab, radiation 1
NCT02554812 Pfizer 94 study locations Advanced cancer CMP-001 Avelumab (anti-PD-L1), utomilumab (4-IBB agonist), PF-04518600(OX40 agonist), PD 0360324 (anti-CSF1) 2
NCT03618641 Diwakar Davar
Checkmate Pharmaceuticals
University of Pittsburgh
UPMC Hillman Cancer Center, Pittsburgh, PA, USA Melanoma, lymph node cancer CMP-001 Nivolumab 2
NCT03084640 Checkmate Pharmaceuticals 4 study locations Malignant melanoma CMP-001 Pembrolizumab 1
NCT02680184 Checkmate Pharmaceuticals 13 study locations Melanoma CMP-001 Pembrolizumab 1
NCT03865082 Idera Pharmaceuticals, Inc.
Bristol-Myers Squibb
3 study locations Solid tumors IMO-2125 Nivolumab (anti-PD1), ipilimumab (anti-CTLA-4) 2
NCT03445533 Idera Pharmaceuticals, Inc.
Bristol-Myers Squibb
102 study locations Metastatic melanoma IMO-2125 Ipilimumab 3
NCT02644967 Idera Pharmaceuticals, Inc. 10 study locations Metastatic melanoma IMO-2125 Ipilimumab, pembrolizumab (anti-PD-1) 1, 2
NCT04126876 A.J.M. van den Eertwegh
Idera Pharmaceuticals, Inc.
VU Medical Center, Amsterdam, the Netherlands Malignant melanoma IMO-2125   2
NCT02077868 Mologen AG 127 study locations Metastatic CRC MGN1703 Usual maintenance 3
NCT02668770 M.D. Anderson Cancer Center
Mologen AG
University of Texas MD Anderson Cancer Center, Houston, TX, USA Advanced cancers, melanoma MGN1703 Ipilimumab 1
NCT02452697 David Rizzieri, MD
Agilent Technologies, Inc.
Duke University Health System, Durham, NC, USA Myeloid malignancies, lymphoid malignancies DUK-CPG-001 NK-enriched donor lymphocyte infusion (DLI) 2